Chen, F. et al. Identification of NTCP animal orthologs supporting hepatitis B virus binding and infection. J. Virol. 99:e0183324 (2025)
Chen, Y.-F. A. et al. Assessing the fitness of Epstein-Barr virus following its reactivation. J. Virol. 99:e0062625 (2025)
Hammer, E.* et al. Prediction of COVID-19 disease progression by multiparametric analysis of circulating extracellular vesicles with flow cytometry. J. Virol. 99:e0118925 (2025)
Yan, W.* et al. Emergence and characterization of historically extinct virulent genotype IV Newcastle disease virus in wild and domestic birds: genetic insights, pathogenicity, and vaccine efficacy. J. Virol.:e0164625 (2025)
Adhikary, D. ; Damaschke, J. ; Mautner, J. & Behrends, U. The Epstein-Barr virus major tegument protein BNRF1 is a common target of cytotoxic CD4+ T cells. J. Virol. 94:e00284-20 (2020)
Delecluse, S.* et al. Identification and cloning of a new western Epstein-Barr virus strain that replicates efficiently in primary B cells. J. Virol. 94:e01918-19 (2020)
Bussey, K.A.* et al. Endosomal toll-like receptors 7 and 9 cooperate in detection of murine gammaherpesvirus 68 infection. J. Virol. 93, e01173-18 (2019)
Hu, J.* ; Protzer, U. & Siddiqui, A.* Revisiting hepatitis B virus: Challenges of curative therapies. J. Virol. 93:e01032-19 (2019)
Chou, W.M. et al. Establishment and characterization of a novel recombinant reporter HBV utilizing the Cre-lox recombination system. J. Virol. 25, 37-37 (2018)
Delecluse, S.* et al. Epstein-Barr virus induces expression of the LPAM-1 integrin in B cells in vitro and in vivo. J. Virol. 93:e01618-18 (2018)
Feuerherd, M. et al. Altered HBV-specific CD4+T-cell Responses in HBV/HIV-1 Co-versus HBV Mono-infected Patients. J. Virol. 25, 52-53 (2018)
Freudenberger, N. ; Meyer, T.* ; Groitl, P. ; Dobner, T.* & Schreiner, S. HAdV protein V core protein is targeted by the host SUMOylation machinery to limit essential viral functions. J. Virol. 92:e01451-17 (2018)
Gilabert-Alarcon, C. et al. Effects of reclaimed water discharge in the Maneadero coastal aquifer, Baja California, Mexico. J. Virol. 92, 121-139 (2018)
González-Hernández, M.* et al. A GXXXA motif in the transmembrane domain of the Ebola virus glycoprotein is required for tetherin antagonism. J. Virol. 92:13 e00403-18 (2018)
Hoffmann, M.* et al. Tetherin inhibits nipah Vvrus but not ebola virus replication in fruit bat cells. J. Virol. 93:01821-18 (2018)
Karimzadeh, H. et al. Amino acid substitutions within HLA-B*27-restricted T cell epitopes prevent recognition by hepatitis delta virus-specific CD8+ T cells. J. Virol. 92:13 e01891-17 (2018)
Menni, C.* et al. Glycosylation profile of immunoglobulin G is cross-sectionally associated with cardiovascular disease risk score and subclinical atherosclerosis in two independent cohorts. J. Virol. 122, 1555-1564 (2018)
Müncheberg, S. et al. E1B-55K mediated regulation of RNF4 STUbL promotes HAdV gene expression. J. Virol. 92, e00164-18 (2018)
Ning, X.* et al. Common and distinct capsid and surface protein requirements for secretion of complete and genome-free hepatitis B virions. J. Virol. 92:e00272-18 (2018)
Reichel, A.* et al. Chromatin-remodeling factor SPOC1 acts as a cellular restriction factor against human cytomegalovirus by repressing the major immediate early promoter. J. Virol. 92:e00342-18 (2018)
Schreiber, S. ; Honz, M. ; Schiemann, M.* ; Protzer, U. & Wisskirchen, K. Generating CD4+T cells for the T-cell therapy of HBV infection. J. Virol. 25, 47-47 (2018)
Stadler, D. et al. Identification of ISG20 as the nuclease involved in Interferon-induced decline of HBV cccDNA. J. Virol. 25, 17-17 (2018)
Suffner, S. et al. Domains of the hepatitis B virus small surface protein S mediating oligomerization. J. Virol. 92:e02232-17 (2018)
Albanese, M. ; Tagawa, T. ; Buschle, A. & Hammerschmidt, W. MicroRNAs of Epstein-Barr virus control innate and adaptive anti-viral immunity. J. Virol. 91:e01667-16 (2017)
Inturi, R.* ; Mun, K.* ; Singethan, K. ; Schreiner, S. & Punga, T.* Human adenovirus infection causes cellular E3 ubiquitin ligase MKRN1 degradation involving the viral core protein pVII. J. Virol. 92:e01154-17 (2017)
Shinde, P.V.* et al. Tumor necrosis factor-mediated survival of CD169+ cells promotes immune activation during vesicular stomatitis virus infection. J. Virol. 92, DOI: 10.1128/JVI.01637-17 (2017)
Bayer, K. ; Banning, C.* ; Bruss, V. ; Wiltzer-Bach, L.* & Schindler, M. Hepatitis C virus is released via a non-canonical secretory route. J. Virol. 90, 10558-10573 (2016)
Brinkmann, C.* et al. Tetherin antagonism by the Ebola virus glycoprotein requires an intact receptor-binding domain and can be blocked by GP1-specific antibodies. J. Virol. 90, 11075-11086 (2016)
Chachage, M.* et al. CD25+ FoxP3+ memory CD4 T cells are frequent targets of HIV infection in vivo. J. Virol. 90, 8954-8967 (2016)
Berrios, C.* et al. Malawi polyomavirus is a prevalent human virus that interacts with known tumor suppressors. J. Virol. 89, 857-862 (2015)
Bürck, C.* et al. KAP1 is a host restriction factor that promotes HAdV E1B-55K SUMO modification. J. Virol. 90, 930-946 (2015)
Cui, X.* ; Luckenbaugh, L.* ; Bruss, V. & Hu, J.J.* Alteration of mature nucleocapsid and enhancement of covalently closed circular DNA formation by Hepatitis B Virus core mutants defective in complete virion formation. J. Virol. 89, 10064-10072 (2015)
Gnirß, K.* et al. Tetherin sensitivity of influenza A viruses is strain specific: Role of hemagglutinin and neuraminidase. J. Virol. 89, 9178-9188 (2015)
Gondim, M.V. et al. AP-2 is the crucial clathrin adaptor protein for CD4 downmodulation by HIV-1 Nef in primary infected CD4+ T cells. J. Virol. 89, 12518-12524 (2015)
Hoh, A.* et al. HBV-infected HepG2hNTCP cells serve as a novel immunological tool to analyze the antiviral efficacy of CD8+ T cells in vitro. J. Virol. 89, 7433-7438 (2015)
Lambelé, M.* et al. Vpu is the main determinant for tetraspanin downregulation in HIV-1 infected cells. J. Virol. 89, 3247-3255 (2015)
Orabi, A. ; Bieringer, M. ; Geerlof, A. & Bruss, V. An aptamer against the matrix binding domain on the hepatitis B virus capsid impairs virion formation. J. Virol. 89, 9281-9287 (2015)
Steinbrück, L. et al. K1 and K15 of Kaposi sarcoma-associated herpes virus are partial functional homologues of latent membrane protein 2A of Epstein-Barr virus. J. Virol. 89, 7248-7261 (2015)
Thiele, F. et al. MVA-infected dendritic cells present CD4+ T-cell epitopes by endogenous MHC class II presentation pathways. J. Virol. 98, 2698-2709 (2015)
Vassena, L.* et al. HIV-1 NEF and VPU interfere with L-selectin (CD62L) cell surface expression to inhibit adhesion and signaling in infected CD4+ t lymphocytes. J. Virol. 89, 5687-5700 (2015)
Bussey, K.* et al. The gammaherpesviruses Kaposi's sarcoma-associated herpesvirus and murine gammaherpesvirus 68 modulate the toll-like receptor-induced proinflammatory cytokine response. J. Virol. 88, 9245-9259 (2014)
Gabaev, I.* et al. Expression of the human cytomegalovirus UL11 glycoprotein in viral infection and evaluation of its effect on virus-epecific CD8 T cells. J. Virol. 88, 14326-14339 (2014)
Price, P.J.* et al. Chemokine (C-C motif) receptor 1 (CCR1) is required for efficient recruitment of neutrophils during respiratory infection with Modified Vaccinia virus Ankara. J. Virol. 88, 10840-10850 (2014)
Weber, E.* et al. Type I interferon protects mice from fatal neurotropic infection with Langat virus by systemic and local anti-viral response. J. Virol. 88, 12202-12212 (2014)
Benhenda, S.* et al. Methyltransferase PRMT1 is a binding partner of HBx and a negative regulator of Hepatitis B Virus transcription. J. Virol. 87, 4360-4371 (2013)
Lankisch, P.* ; Adler, H. & Borkhardt, A.* Testing for herpesvirus infection is essential in children with chromosomal-instability syndromes. J. Virol. 87, 3616-3617 (2013)
Siegler, V.D. & Bruß, V. Role of transmembrane domains of hepatitis B virus small surface proteins in subviral-particle biogenesis. J. Virol. 87, 1491-1496 (2013)
Vidy, A.* et al. Systemic and local infection routes govern different cellular dissemination pathways during gammaherpesvirus infection in vivo. J. Virol. 87, 4596-4608 (2013)
Kalla, M. ; Göbel, C. & Hammerschmidt, W. The lytic phase of Epstein-Barr virus requires a viral genome with 5-methylcytosine residues in CpG sites. J. Virol. 86, 447-458 (2012)
Koppensteiner, H.* ; Banning, C.* ; Schneider, C.* ; Hohenberg, H.* & Schindler, M. Macrophage internal HIV-1 is protected from neutralizing antibodies. J. Virol. 86, 2826-2836 (2012)
Schneider, M. et al. Severe acute respiratory syndrome coronavirus replication is severely impaired by MG132 due to proteasome-independent inhibition of M-calpain. J. Virol. 86, 10112-10122 (2012)
Pascutti, M.F.* et al. Interplay between modified vaccinia virus Ankara and dendritic cells: Phenotypic and functional maturation of bystander dendritic cells. J. Virol. 85, 5532-5545 (2011)
Ruiss, R. et al. A virus-like particle-based Epstein-Barr virus vaccine. J. Virol. 85, 13105-13113 (2011)
Arzberger, S. ; Hösel, M.* & Protzer, U. Apoptosis of hepatitis B virus-infected hepatocytes prevents release of infectious virus. J. Virol. 84, 11994-12001 (2010)
Busse, C.* et al. Epstein-Barr viruses that express a CD21 antibody provide evidence that gp350's functions extend beyond B-cell surface binding. J. Virol. 84, 1139-1147 (2010)
Deutsch, M.J. ; Ott, E. ; Papior, P. & Schepers, A. The latent origin of replication of Epstein-Barr virus directs viral genomes to active regions of the nucleus. J. Virol. 84, 2533-2546 (2010)
Heinzelmann, K. et al. Kaposi's sarcoma-associated herpesvirus viral interferon regulatory factor 4 (vIRF4/K10) is a novel interaction partner of CSL/CBF1, the major downstream effector of Notch signaling. J. Virol. 84, 12255-12264 (2010)
Iskra, S. ; Kalla, M. ; Delecluse, H.J.* ; Hammerschmidt, W. & Moosmann, A. Toll-like receptor agonists synergistically increase proliferation and activation of B cells by Epstein-Barr virus. J. Virol. 84, 3612-3623 (2010)
Zhu, J.Y.* et al. Identification and analysis of expression of novel microRNAs of murine gammaherpesvirus 68. J. Virol. 84, 10266-10275 (2010)
Ejegod, D.* et al. Control of pathogenicity and disease specificity of a T-lymphomagenic gammaretrovirus by E-box motifs but not by an overlapping glucocorticoid response element. J. Virol. 83, 336-346 (2009)
Faumont, N.* et al. C-Myc and Rel/NF-κB are the two master transcriptional systems activated in the latency III program of Epstein-Barr virus-immortalized B cells. J. Virol. 83, 5014-5027 (2009)
Flach, B. ; Steer, B. ; Thakur, N.N. ; Haas, J.* & Adler, H. The M10 locus of murine gammaherpesvirus 68 contributes to both the lytic and the latent phases of infection. J. Virol. 83, 8163-8172 (2009)
Jochmann, R.* et al. O-linked N-acetylglucosaminylation of Sp1 inhibits the human immunodeficiency virus type 1 promoter. J. Virol. 83, 3704-3718 (2009)
Kindsmüller, K.* et al. A 49-kilodalton isoform of the adenovirus type 5 early region 1B 55-kilodalton protein is sufficient to support virus replication. J. Virol. 83, 9045-9056 (2009)
Lehmann, M.H. et al. Modified vaccinia virus ankara triggers chemotaxis of monocytes and early respiratory immigration of leukocytes by induction of CCL2 expression. J. Virol. 83, 2540-2552 (2009)
Pairan, A.* & Bruß, V. Functional surfaces of the hepatitis B virus capsid. J. Virol. 83, 11616-11623 (2009)
Schön, U. et al. Human endogenous retroviral long terminal repeat sequences as cell type-specific promoters in retroviral vectors. J. Virol. 83, 12643-12650 (2009)
Adhikary, D. ; Behrends, U. ; Feederle, R.* ; Delecluse, H.J.* & Mautner, J. Standardized and highly efficient expansion of Epstein-Barr virus-specific CD4+ T cells by using virus-like particles. J. Virol. 82, 3903-3911 (2008)
Frank, O.* et al. Variable transcriptional activity of endogenous retroviruses in human breast cancer. J. Virol. 82, 1808-1818 (2008)
le Clorennec, C.* et al. Molecular basis of cytotoxicity of Epstein-Barr virus (EBV) latent membrane protein 1 (LMP1) in EBV latency III B cells: LMP1 induces type II ligand-independent autoactivation of CD95/Fas with caspase 8-mediated apoptosis. J. Virol. 82, 6721-6733 (2008)
Lindner, S.E.* ; Zeller, K. ; Schepers, A. & Sugden, B.* The affinity of EBNA1 for its origin of DNA synthesis is a determinant of the origin's replicative efficiency. J. Virol. 82, 5693-5702 (2008)
Sander, G.* et al. Intracellular localization map of human herpesvirus 8 proteins. J. Virol. 82, 1908-1922 (2008)
Adler, H. ; Steer, B. ; Freimüller, K. & Haas, J.* Murine Gammaherpesvirus 68 Contains Two Functional Lytic Origins of Replication. J. Virol. 81, 7300-7305 (2007)
Boccellato, F.* et al. EBNA2 Interferes with the Germinal Center Phenotype by Downregulating BCL6 and TCL1 in Non-Hodgkin's Lymphoma Cells. J. Virol. 81, 2274-2282 (2007)
Gasteiger, G. ; Kastenmüller, W.* ; Ljapoci, R. ; Sutter, G.* & Drexler, I. Cross-priming of cytotoxic T cells dictates antigen requisites for modified vaccinia virus ankara vector vaccines. J. Virol. 81, 11925-11936 (2007)
Tierney, R.* et al. Epstein-Barr virus exploits BSAP/Pax5 to achieve the B-cell specificity of its growth-transforming program. J. Virol. 81, 10092-10100 (2007)
Feederle, R.* et al. Epstein-barr virus BNRF1 protein allows efficient transfer from the endosomal compartment to the nucleus of primary B lymphocytes. J. Virol. 80, 9435-9443 (2006)
Goormachtigh, G.* et al. Autoactivation of the Epstein-barr virus oncogenic protein LMP1 during type II latency through opposite roles of the NF-kB and JNK signaling pathways. J. Virol. 80, 7382-7393 (2006)
Maier, S. et al. Cellular target genes of Epstein-Barr virus nuclear antigen 2. J. Virol. 80, 9761-9771 (2006)
Milosevic, S. ; Behrends, U. ; Adhikary, D. & Mautner, J. Identification of major histocompatibility complex class II-restricted antigens and epitopes of the Epstein-barr virus by a novel bacterial expression cloning approach. J. Virol. 80, 10357-10364 (2006)
Pegman, P.M.* et al. Epstein-Barr virus nuclear antigen 2 trans-activates the cellular antiapoptotic bfl-1 gene by a CBF1/RBPJk-dependent pathway. J. Virol. 80, 8133-8144 (2006)
Stengel, A. et al. Expression profiles of endogenous in Old World Monkeys. J. Virol. 80, 4415-4421 (2006)
Stengel, A. et al. Expression profiles of endogenous retroviruses in Old World monkeys. J. Virol. 80, 4415-4421 (2006)
Frank, O.* et al. Human endogenous retrovirus expression profiles in samples from brains of patients with schizophrenia and bipolar disorders. J. Virol. 79, 10890-10901 (2005)
Kelly, G.K.* et al. Epstein-barr virus nuclear antigen 2 (EBNA2) gene deletion is consistently linked with EBNA3A,-3B and -3C expression in burkitt's lymphoma cells and with increased resistance to apoptosis. J. Virol. 79, 10709-10717 (2005)
Ludwig, H.* et al. Role of viral factor E3L in modified vaccinia virus Ankara infection of human HeLa cells: Regulation of the virus life cycle and identification of differentially expressed host genes. J. Virol. 79, 2584-2596 (2005)
Maier, S. et al. A somatic knockout of CBF1 in a human B-cell line reveals that induction of CD21 and CCR7 by EBNA-2 is strictly CBF1 dependent and that downregulation of immunoglobulin M is partially CBF1 independent. J. Virol. 79, 8784-8792 (2005)
Najjar, I.* ; Schlee, M. & Bornkamm, G.W. Latent membrane protein 1 regulates STAT1 through NF-kB-dependent interferon secretion in Epstein-Barr virus-immortalized B cells. J. Virol. 79, 4936-4943 (2005)
Nielsen, A.A.* ; Sorensen, A.B.* ; Schmidt, J. & Pedersen, F.S.* Analysis of wild-type and mutant SL3-3 murine leukemia virus insertions in the c-myc promoter during lymphomaganesis reveals target site hot spots, virus-dependent patterns, and frequent error-prone gap repair. J. Virol. 79, 67-78 (2005)
Peng, R.* ; Moses, S.C.* ; Tan, J.* ; Kremmer, E. & Ling, P.D.* The Epstein-Barr virus EBNA-LP protein preferentially coactivates EBNA2-mediated stimulation of latent membrane proteins expressed from the viral divergent promoter. J. Virol. 79, 4492-4505 (2005)
Seifarth, W.* et al. Comprehensive analysis of human endogenous retrovirus transcriptional activity in human tissues with a retrovirus-specific microarray. J. Virol. 79, 341-352 (2005)
Smulevitch, S.* et al. Structural and functional analysis of the RNA transport element, a member of an extensive family present in the mouse genome. J. Virol. 79, 2356-2365 (2005)
Gordadze, A.V.* et al. EBNA2 amino acids 3 to 30 are required for induction of LMP-1 and immortalization maintenance. J. Virol. 78, 3919-3929 (2004)
Lee, J.M.* et al. EBNA2 is required for protection of latently Epstein-Barr virus-infected B cells against specific apoptotic stimuli. J. Virol. 78, 12694-12697 (2004)
Ruvolo, V.* et al. Functional analysis of Epstein-Barr virus SM protein: Identification of amino acids essential for structure, transactivation, splicing inhibition and virion production. J. Virol. 78, 2-13 (2004)
Schlee, M. et al. Identification of Epstein-Barr virus (EBV) nuclear antigen 2 (EBNA2) target proteins by proteome analysis: Activation of EBNA2 in conditionally immortalized B cells reflects early events after infection of primary b cells by EBV. J. Virol. 78, 3941-3952 (2004)
Stewart, J.P.* et al. In vivo function of a gammaherpesvirus virion glycoprotein: Influence on B-cell infection and mononucleosis. J. Virol. 78, 10449-10459 (2004)
Sørensen, K.D.* ; Quintanilla-Martinez, L. ; Kunder, S. ; Schmidt, J. & Pedersen, F.S.* Mutation of all runx (AML1/Core) sites in the enhancer of T-lymphomagenic SL3-3 murine leukemia virus unmasks a significant potential for myeloid leukemia induction and favors enhancer evolution toward induction of other disease patterns. J. Virol. 78, 13216-13231 (2004)
Brinkmann, M.M.* et al. Activation of Mitogen-Activated Protein Kinase and NF-kB Pathways by a Kaposi's Sarcoma- Associated Herpesvirus K15 Membrane Protein. J. Virol. 77, 9346-9358 (2003)
Dudziak, D. et al. Latent Membrane Protein 1 of Epstein-Barr Virus Induces CD83 by the NF-kB Signaling Pathway. J. Virol. 77, 8290-8298 (2003)
Herzer, K.* et al. Upregulation of Major Histocompatibility Complex Class I on Liver Cells by Hepatitis C Virus Core  Protein via p53 and TAP1 Impairs Natural Killer Cell Cytotoxicity. J. Virol. 77, 8299-8309 (2003)
Hornemann, S. et al. Replication of Modified Vaccinia Virus Ankara in Primary Chicken Embryo Fibroblasts Requires Expression of the Interferon Resistance Gene E3L. J. Virol. 77, 8394-8407 (2003)
Öhlschläger, P.* et al. Human papillomavirus type 16 L1 capsomeres induce L1-specific cytotoxic T lymphocytes and tumor regression in C57BL/6 mice. J. Virol. 77, 4635-4645 (2003)
Vogel, T.U.* et al. Multispecific vaccine-induced mucosal cytotoxic T lymphocytes reduce acute-phase viral replication but fail in long-term control of simian immunodeficiency virus SIVmac239. J. Virol. 77, 13348-13360 (2003)
Allen, T.M.* et al. Tat-Vaccinated Macaques Do Not Control Simian Immunodeficiency Virus SIVmac239  Replication. J. Virol. 76, 4108-4112 (2002)
Gruffat, H.* et al. Epstein-Barr Virus mRNA Export Factor EB2 is Essential for Production of Infectious Virus. J. Virol. 76, 9635-9644 (2002)
Guérin, J.-L.* et al. Myxoma Virus Leukemia-Associated Protein is Responsible for Major Histocompatibility  Complex Class I and Fas-CD95 Down-Regulation and Defines Scrapins, a New Group of Surface Cellular Receptor Abductor Proteins. J. Virol. 76, 2912-2923 (2002)
Horton, H.* et al. Immunization of rhesus macaques with a DNA prime/modified vaccinia virus Ankara boost regimen induces broad simian immunodeficiency virus (SIV)-specific T-cell responses and reduces initial viral replication but does not prevent disease progression following challenge with pathogenic SIVmac239. J. Virol. 76, 7187-7202 (2002)
Ried, M.U.* ; Girod, A.* ; Leike, K.* ; Buning, H.* & Hallek, M. Adeno-Associated Virus Capsids Displaying Immunoglobulin-Binding Domains Permit Antibody- Mediated Vector Retargeting to Specific Cell Surface Receptors. J. Virol. 76, 4559-4566 (2002)
Nappi, F.* et al. Identification of a novel posttranscriptional regulatory element by using a rev- and RRE-mutated human immunodeficiency virus type 1 DNA proviral clone as a molecular trap. J. Virol. 75, 4558-4569 (2001)
Rimessi, P.* et al. Transcription Pattern of Human Herpesvirus 8 Open Reading Frame K3 in Primary Effusion Lymphoma and KaposiS Sarcoma. J. Virol. 75, 7161-7174 (2001)
Janz, A. et al. Infectious Epstein-Barr virus lacking major glycoprotein BLLF1 (gp350/220) demonstrates the existence of additional viral ligands. J. Virol. 74, 10142-10152 (2000)
Strobl, L.J. et al. Activated Notch1 modulates gene expression in B cells similary to Epstein-Barr viral nuclear antigen 2. J. Virol. 74, 1727-1735 (2000)
Ludwig, E. et al. Diminished rev-mediated stimulation of human immunodeficiency virus type 1 protein synthesis is a hallmark of human astrocytes. J. Virol. 73, 8279-8289 (1999)
Nevels, M.* et al. Transforming potential of the adenovirus type 5 E4orf3 protein. J. Virol. 73, 1591-1600 (1999)
Baumann, M. et al. Activation of the Epstein-Barr virus transcription factor BZLF1 by 12-O-tetradecanoylphorbol-13-acetate-induced phosphorylation. J. Virol. 72, 8105-8114 (1998)
Kempkes, B. ; Pich, D. ; Zeidler, R. ; Sugden, B.* & Hammerschmidt, W. Immortalization of human B lymphocytes by a plasmid containing 71 kilobase pairs of Epstein-Barr virus DNA. J. Virol. 69, 231-238 (1995)
Meitinger, C. ; Strobl, L.J. ; Marschall, G. ; Bornkamm, G.W. & Zimber-Strobl, U. Crucial sequences within the Epstein-Barr virus TP1 promoter for EBNA2- mediated transactivation and interaction of EBNA2 with its responsive element. J. Virol. 68, 7497-7506 (1994)
Bornkamm, G.W. ; Delecluse, H.-J. ; Hammerschmidt, W. & Bullerdiek, J. Episomal and Integrated Copies of Epstein-Barr Virus Coexist in Burkitt Lymphoma Cell Lines. J. Virol. 67, 1292-1299 (1993)
Delecluse, H.J. ; Bartnizke, S.* ; Hammerschmidt, W. ; Bullerdiek, J.O.* & Bornkamm, G.W. Episomal and integrated copies of Epstein-Barr virus coexist in Burkitt lymphoma cell lines. J. Virol. 67, 1292-1299 (1993)
Delecluse, H.J. & Hammerschmidt, W. Status of Marek's disease virus in established lymphoma cell lines: Herpesvirus integration is common. J. Virol. 67, 82-92 (1993)
Schepers, A. ; Pich, D. ; Mankertz, J. & Hammerschmidt, W. Cis-acting Elements in the Lytic Origin of DNA Replication of Epstein-Barr Virus. J. Virol. 67, 4237-4245 (1993)
Schepers, A. ; Pich, D. ; Mankertz, J. & Hammerschmidt, W. cis-acting elements in the lytic origin of DNA replication of Epstein-Barr virus. J. Virol. 67, 4237-4245 (1993)
Hoffmann-Fezer, G. et al. Decline in CD4+ cell numbers in cats with naturally acquired feline immunodeficiency virus infection. J. Virol. 66, 1484-1488 (1992)
Zimber-Strobl, U. et al. Epstein-Barr Virus Nuclear Antigen 2 Activates Transcription of the Terminal Protein Gene. J. Virol. 65, 415-423 (1991)
Cordier, M. et al. Stable Transfection of Epstein-Barr Virus (EBV) Nuclear Antigen 2 in Lymphoma Cells Containing the EBV P3HR1 Genome Induces Expression of B-Cell Activation Molecules CD21 and CD23. J. Virol. 64, 1002-1013 (1990)
Frech, B. et al. Identification of Epstein-Barr Virus Terminal Protein 1 (TP1) in Extracts of Four Lymphoid Cell  Lines, Expression in Insect Cells, and Detection of Antibodies in Human Sera. J. Virol. 64, 2759-2767 (1990)
Rowe, D.T. ; Hall, L. ; Joab, I. & Laux, G. Identification of the Epstein-Barr Virus Terminal Protein Gene Products in Latently Infected  Lymphocytes. J. Virol. 64, 2866-2875 (1990)
Salmons, B. ; Erfle, V. ; Brem, G. & Günzburg, W.H. naf, a Trans-regulating Negative Acting Factor Encoded  within the Mouse Mammary Tumour Virus 0RF Region. J. Virol. (1990)
Salmons, B.* ; Erfle, V.F. ; Brem, G.* & Günzburg, W.H. Naf, a trans-regulating negative-acting factor encoded within the mouse mammary tumor virus open reading frame region. J. Virol. 64, 6355-6359 (1990)
Bode, W. Regulation of late functions in Salmonella bateriophages P22 and L studied by assaying endolysin synthesis. J. Virol. 32, 1-7 (1979)